Striking new figures from the Office for National Statistics (ONS) reveals millennials (people born between around 1981-1996) ...

Canalevia®-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDABy prescription only, Canalevia-CA1 is a canine-specific ...

The MAP Group, a pan-European specialist pharmaceutical and biotechnology strategic consultancy focused on driving therapies through the complex medical, regulatory and market access landscape to ...

OMAHA, NB / ACCESSWIRE / November 6, 2024 / In honor of breast cancer awareness month, Fusion held a company outing and fundraiser last month, raising more than $20,000 for breast cancer support and ...

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now ...

Quell Therapeutics Ltd (“Quell”), a world leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces that management will ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

FORT LAUDERDALE, FL / ACCESSWIRE / November 6, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...

DALLAS, TX / ACCESSWIRE / November 6, 2024 / Adnexus Biotechnologies Inc. is pleased to announce the completion of a merger agreement with Sanctum Therapeutics Corporation to acquire Sanctum ...

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a ...

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, ...